(Q38997526)

English

Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection

scientific article published on 4 November 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

0 references

1 reference

Europe PubMed Central

Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Roger Bedimo

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Lisa Rosenblatt

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Joel Myers

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

246-266

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

1 November 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Renal safety of tenofovir in HIV treatment-experienced patients.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Association of tenofovir exposure with kidney disease risk in HIV infection

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir renal toxicity targets mitochondria of renal proximal tubules

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 result

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)

1 reference

https://api.crossref.org/works/10.1080%2F15284336.2016.1243363

21 January 2018

Identifiers

10.1080/15284336.2016.1243363

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38997526&oldid=1801633194"